Foretinib Completed Phase 2 Trials for Recurrent Breast Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01147484A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer